Barcelona, Spain — BrainOmega Tech S.L. (“BrainOmega”), a Generative AI company working across pharma and biotech, has begun fundraising with a target of €2 million. If the full amount is raised, the company plans to use the funding over approximately 30 months to expand its Barcelona team, develop its foundation models and discovery platform, and pursue research collaborations with pharmaceutical and biotechnology partners.
BrainOmega develops computational tools that help research teams prioritise small-molecule and RNA candidates for experimental validation.
Moving more of drug and vaccine discovery into software
Bringing a medicine to patients takes many years, and most candidates fail along the way, often late and at great cost. BrainOmega’s view is that much more of that work can happen in software, where ideas are faster to test, cheaper to discard and easier to check before they reach the lab.
Founded in Barcelona in 2026, BrainOmega offers two products at oncomega.app:
- Drug Discovery, a Generative AI workspace for small-molecule programmes, from target identification to a prioritised shortlist of candidates.
- RNA Discovery, for research across RNA classes, from microRNAs and tRNA fragments to circular RNAs and mRNA neoantigens.
Both run on the company’s own foundation models and show researchers the evidence and rationale behind their results, so that a prediction can be checked rather than taken on trust. BrainOmega works alongside universities, public bodies and supercomputing centres across Catalonia’s research and innovation ecosystem.
Use of funds
The target reflects the company’s current operating plan. If the full amount is raised, BrainOmega plans to:
- grow its team in Barcelona, starting with the leadership roles below;
- continue developing its foundation models and both products;
- pursue more research collaborations with pharma and biotech partners.
Building the team
BrainOmega is building its leadership team in Barcelona, with open roles for a Chief Technology Officer and a Head of Business. Details are on the careers page.
Investor enquiries
AI, Life sciences, and deep-tech investors interested in an introductory conversation can contact contact@brainomega.ai.
This announcement is for information only. It is not an offer to sell, or a solicitation of an offer to buy, any securities of BrainOmega Tech S.L. in any jurisdiction, and it must not be relied on in connection with any investment decision. Any investment would be made only on the basis of definitive documentation and only by persons to whom such an offer may lawfully be made. Statements about the company’s plans describe its current intentions and may change.